Dana Farber ( Dana Farber)

Primary tabs

Dana Farber's picture

Management

Contact Address

About Dana Farber

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Dana Farber press release, blog etc

Thu, 01/15/2026 - 17:05 Dana-Farber receives widespread support for proposed proton therapy center in Boston
Wed, 01/14/2026 - 18:17 Dr. Mariella Filbin Receives 2026 Emerging Leader Award from The Mark Foundation
Wed, 12/17/2025 - 17:46 Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
Fri, 12/12/2025 - 15:05 Mobile Health Tool Helps Improve Quality of Life For Young Breast Cancer Survivors
Mon, 12/08/2025 - 17:21 Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
Mon, 12/08/2025 - 17:21 Sara Tolaney Honored With AACRs Outstanding Investigator Award for Breast Cancer Research
Mon, 12/08/2025 - 17:21 Childhood leukemia care puts one in three families at risk of poverty
Mon, 12/08/2025 - 17:21 Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer
Mon, 12/08/2025 - 17:21 Dana-Farber Cancer Institute drives deep remissions in Waldenstroms with targeted, time limited therapies
Sun, 12/07/2025 - 12:05 Sickle-cell disease associated with early onset of clonal hematopoiesis, a precancerous condition
Sun, 12/07/2025 - 12:04 Dana-FarberLed Studies in Sickle Cell Disease, Waldenstroms, Follicular and Mantle Cell Lymphomas, and MDS at ASH 2025
Sun, 12/07/2025 - 11:57 Gordon Freeman Receives Inaugural Gretener-Thurlemann Prize, Recognizing Breakthrough Research into Cancer Immunotherapy
Sun, 12/07/2025 - 11:57 Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)
Mon, 11/24/2025 - 18:22 Dana-FarberLed Studies in Sickle Cell Disease, Waldenstroms, Follicular and Mantle Cell Lymphomas, and MDS Presented at ASH 2025
Mon, 11/24/2025 - 18:21 Dana-Farber Cancer Institute is awarded $20 million grant from the Elaine and Eduardo Saverin Foundation
Wed, 10/29/2025 - 22:34 Dana-Farbers Sleep ALL Night Program Helps Children with Leukemia Sleep Better During Treatment
Wed, 10/22/2025 - 08:39 ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Wed, 10/22/2025 - 08:38 Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
more

InfoBox

HomePagewww.dana-farber.org
Facebookwww.facebook.com/danafarbercancerinstitute
Twittertwitter.com/danafarber
YouTubewww.youtube.com/user/DanaFarberCancerInst
Google+plus.google.com/114201765956539393893?prsrc=3
Instagraminstagram.com/danafarber
Pinterestpinterest.com/DFCI
LinkedInwww.linkedin.com/company/dana-farber-cancer-institute
Wikipediaen.wikipedia.org/wiki/Dana%E2%80%93Farber_Cancer_Institute